netFormulary Kettering General Hospital NHS
NHS Foundation Trust  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  CDK inhibitors
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab to top
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase to top
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Abemaciclib (Verzenios®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
NHS England

50mg, 100mg and 150mg film coated tablets.


For use in accordance with relevant NICE Technology Appraisals


 

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Alectinib 150mg hard capsules (Alecensa®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA229: Leukaemia (chronic myeloid) - bosutinib (NOT RECOMMENDED)
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Brigatinib (Alunbrig®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
Cancer Drugs Fund
NHS England
 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA296: Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Dacomitinib (Vizimpro®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA595:; Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Dasatinib  (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
Cancer Drugs Fund
Tablets: 20mg, 50mg and 70mg 
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Entrectinib 100mg capsules (Rozlytrek®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
   
Erlotinib (Tarceva®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
Tablets: 25mg, 100mg and 150mg 
Link  NICE TA162: Lung cancer (non-small-cell) - erlotinib
Link  NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Link  NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Everolimus Tablets  (Afinitor® and Votubia®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted Everolimus is to be used as part of a clinical trial only.

Tablets:
2.5mg
5mg
10mg 
Link  NICE TA295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (Not recommended)
Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib Tablets 250mg (Iressa®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
 
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Gilteritinib 40mg tablets (Xospata®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
   
Ibrutinib capsules 140mg (Imbruvica®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Cytotoxic Drug Imatinib Tablets 100mg and 400mg (Gilvec®)
View adult BNF View SPC online View childrens BNF
Formulary  
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196)
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Ixazomib (Ninlaro®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Neratinib
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England
 
Link  NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
   
Nilotinib Capsules 200mg (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary  
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Palbociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
Cancer Drugs Fund
BlueTeq
 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ribociclib (Kisqali®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA356: Ruxolitinib for treating polycythaemia vera (terminated appraisal)
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
08.01.05  Expand sub section  Tezanes
08.01.05  Expand sub section  Topoisimerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Afatinib tablets  (Giotrif®)

View adult BNF View SPC online View childrens BNF
Non Formulary Relevant service not provided at KGH
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
 
Cabozantinib tablets  (Cabometyx®)

View adult BNF View SPC online View childrens BNF
Non Formulary Relevant service not provided at KGH
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
 
Dabrafenib capsules  (Tafinlar®)

View adult BNF View SPC online View childrens BNF
Non Formulary Relevant service not provided at KGH
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
 
Lapatinib  (Tyverb®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
 
Lenvatinib  (Kisplyx®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
 
Cytotoxic Drug  Midostaurin capsules 25mg  (Rydapt®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
 
Cytotoxic Drug  Regorafenib  (Stivarga®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
 
Sorafenib  (Nexavar®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sunitinib  (Sutent®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Vemurafenib  (Zelboraf®)

View adult BNF View SPC online View childrens BNF
Non Formulary Relevant service not provided at KGH
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber 1

"Amber 1" - These are medicines that require significant monitoring and the decision to treat with an AMBER medicine should be made by specialists only  

Amber 2

"Amber 2" - These are medicines that require little or no monitoring by the GP, but should only be prescribed in general practice after they have been recommended following specialist referral.  

Red

"Red" - Secondary care only  

RedRed

"Double Red" - NOT recommended for prescribing in either primary or secondary care  

Grey

Traffic light status to be confirmed  

Green

May be prescribed in primary and secondary care  

netFormulary